



STATE OF OKLAHOMA
OKLAHOMA HEALTH CARE AUTHORITY

OHCA 2019-08

July 24, 2019

RE: Prior Authorization Changes for Medication Assisted Treatment – Effective July 31, 2019

Dear Provider,

The Oklahoma Health Care Authority (OHCA), in an effort to combat the prescription drug abuse epidemic in Oklahoma, is improving access for SoonerCare members to medication assisted treatment (MAT). The OHCA is currently working to change prior authorization (PA) requirements for MAT. **Effective July 31st, 2019**, the OHCA will no longer require a PA on select products.

No Prior Authorization Required	Prior Authorization Required
<ul style="list-style-type: none">Suboxone® (buprenorphine/naloxone SL films)(BRAND PREFERRED)buprenorphine/naloxone SL tablets (Generic ONLY)Vivitrol® (naltrexone injection)	<ul style="list-style-type: none">Bunavail® (buprenorphine/naloxone buccal films)Zubsolv® (buprenorphine/naloxone SL tablets)buprenorphine SL tablets (Subutex®)Probuphine® (buprenorphine implant)Lucemyra™ (lofexidine)Sublocade™ (buprenorphine ER injection)buprenorphine/naloxone SL films (generic)

SL = sublingual; PA = prior authorization; ER = extended-release

The prescription must be prescribed by a provider with a DEA “X” number. If the provider does not have a DEA “X” number, or if it is not on the provider’s OHCA provider file, the claim will deny at the pharmacy point of sale. Please ensure your DEA “X” number is current and on file by emailing ProviderEnrollment@okhca.org.

For pregnant members, the single ingredient buprenorphine tablets will not require a PA; however, a pregnancy diagnosis must be present in the member’s recent SoonerCare claims history for the claim to pay without a PA.

The daily limits for all buprenorphine-containing products used for MAT will be 16 mg bioequivalent buprenorphine per day. A prior authorization will be required for members exceeding the 16mg bioequivalent buprenorphine limit per day and each request will be evaluated on a case-by-case basis. For additional information regarding the continued PA requirements, visit: www.okhca.org/MAT.

If the member requires a product with a continued PA requirement, the request form can be located on the SoonerCare website (www.okhca.org/rxforms).

Please note: Medications for MAT will continue to be exempt from the opioid morphine milligram equivalent (MME) limit implementation. For additional information regarding the opioid MME limit implementation or opioid prescribing guidelines, visit: <http://www.okhca.org/OPG>. For more information regarding the current opioid epidemic in Oklahoma, MAT, and a list of available treatment centers and resources, visit: <https://okimready.org/>.

For more information on Oklahoma opioid prescribing and dispensing guidelines, visit: https://www.ok.gov/health/Protective_Health/Injury_Prevention_Service/Drug_Overdose/Opioid_Prescribing_Guidelines/index.html

Thank you for your continued service to our SoonerCare members.

Sincerely,

Rebecca Pasternik-Ikard
Chief Executive Officer